Ton N M Schumacher
Overview
Explore the profile of Ton N M Schumacher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
6279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boon N, Oliveira R, Korner P, Kochavi A, Mertens S, Malka Y, et al.
Science
. 2024 May;
384(6697):785-792.
PMID: 38753784
In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown....
2.
Kaptein P, Slingerland N, Metoikidou C, Prinz F, Brokamp S, Machuca-Ostos M, et al.
Cancer Discov
. 2024 Apr;
14(7):1226-1251.
PMID: 38563969
Tumor-specific CD8+ T cells are key effectors of antitumor immunity but are often rendered dysfunctional in the tumor microenvironment. Immune-checkpoint blockade can restore antitumor T-cell function in some patients; however,...
3.
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Moynihan K, Kumar M, Sultan H, Pappas D, Park T, Chin S, et al.
Cancer Discov
. 2024 Apr;
14(7):1206-1225.
PMID: 38563906
IL2 signals pleiotropically on diverse cell types, some of which contribute to therapeutic activity against tumors, whereas others drive undesired activity, such as immunosuppression or toxicity. We explored the theory...
4.
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, et al.
Cancer Cell
. 2023 Sep;
41(10):1817-1828.e9.
PMID: 37683639
The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a...
5.
van der Leun A, Traets J, Vos J, Elbers J, Patiwael S, Qiao X, et al.
Cancer Discov
. 2023 Aug;
13(10):2212-2227.
PMID: 37548431
Significance: In head and neck squamous cell carcinoma, neoadjuvant PD-1/CTLA4 blockade has shown substantial response rates (20%-35%). As recognition of tumor antigens by T cells appears to be a critical...
6.
Ribas A, Nicholas Haining W, Schumacher T
Cancer Discov
. 2022 Oct;
12(10):2244-2248.
PMID: 36196573
Tumor-specific cytotoxic T cells unleashed by the blockade of immune checkpoints have to overcome a hostile tumor microenvironment (TME). They start from very small numbers of T cells with tumor...
7.
Publisher Correction: Long-distance modulation of bystander tumor cells by CD8 T-cell-secreted IFN-γ
Hoekstra M, Bornes L, Dijkgraaf F, Philips D, Pardieck I, Toebes M, et al.
Nat Cancer
. 2022 Feb;
1(7):749.
PMID: 35122043
No abstract available.
8.
Dijkgraaf F, Kok L, Schumacher T
Cold Spring Harb Perspect Biol
. 2021 Mar;
13(8).
PMID: 33685935
Resident memory CD8 T (Trm) cells permanently reside in nonlymphoid tissues where they act as a first line of defense against recurrent pathogens. How and when antigen-inexperienced CD8 T cells...
9.
Hoefsmit E, Rozeman E, Van T, Dimitriadis P, Krijgsman O, Conway J, et al.
J Immunother Cancer
. 2020 Dec;
8(2).
PMID: 33262254
Background: The profound disparity in response to immune checkpoint blockade (ICB) by cutaneous melanoma (CM) and uveal melanoma (UM) patients is not well understood. Therefore, we characterized metastases of CM...
10.
Hoekstra M, Bornes L, Dijkgraaf F, Philips D, Pardieck I, Toebes M, et al.
Nat Cancer
. 2020 Jun;
1(3):291-301.
PMID: 32566933
T cell-secreted IFNγ can exert pleiotropic effects on tumor cells that include induction of immune checkpoints and antigen presentation machinery components, and inhibition of cell growth. Despite its role as...